tablets

The tablet design with a cap portion having specific curvature and a non-printing area addresses cracking and chipping issues, while ensuring clear identification, enhancing the durability and visibility of magnesium oxide tablets.

JP2025005031AActive Publication Date: 2025-01-16SETOLAS HLDG INC
View PDF 2 Cites 0 Cited by

Patent Information

Application Number
JP2023105015
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Filing Date
2023-06-27
Publication Date
2025-01-16
Estimated Expiration
2043-06-27

AI Technical Summary

Technical Problem

Conventional tablets containing magnesium oxide particles face issues with cracking and chipping during manufacturing, and there is a risk of missing identification information due to contact between tablets during the process.

Method used

The tablet design includes a columnar body with a cap portion that has a specific radius of curvature and a non-printing area, along with a printing area on the cap section, ensuring a balanced distribution of curvature and minimizing contact points to prevent cracking and chipping, while maintaining clear identification information.

Benefits of technology

The design effectively suppresses the occurrence of poor appearance by reducing cracking, chipping, and missing characters, ensuring the tablets maintain their shape and legibility during handling and transportation.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 2025005031000001_ABST
    Figure 2025005031000001_ABST
Patent Text Reader

Abstract

To provide tablets that suppress the occurrence of appearance defects.SOLUTION: A tablet 10 comprises a cylindrical body 12, a cap portion 14 having a surface protruding in a height direction H, and a printed portion 16 printed on the cap portion 14. The cap portion 14 of a circular shape when viewed from the height direction, has a central portion 18 extending in a plane direction intersecting with the height direction H, and a peripheral portion 20 continuous with an outer edge of the central portion 18. In a cross-sectional view including a central axis of the body 12, a curvature radius R1 of a surface of the central portion 18 and a curvature radius R2 of a surface of the peripheral portion 20 are within a range of ±10% of values calculated by the following formulas (1) and (2), respectively, when a diameter of the cap portion 14 viewed from the height direction H is defined as RC. A non-printed region 24 includes a region of at least 2.6% of a surface area of the cap portion 14, and is a region of 14.5% or less of the surface area of the cap portion 14. The printed portion 16 is provided in a printed region 26 excluding the non-printed region 24. R1=3.226RC-6.983...(1). R2=0.437RC-0.231...(2).SELECTED DRAWING: Figure 1
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] The present invention relates to a tablet, and in particular to a tablet having identification information, such as letters, symbols, or figures, printed thereon. [Background technology]

[0002] Conventionally, tablets containing magnesium oxide particles as a main component have been known as antacid or laxative tablets, and their usage has been expanding recently. The tablets containing magnesium oxide particles are produced, for example, by blending magnesium oxide particles with additives such as a binder and a disintegrant, and tableting the mixture. For example, Patent Document 1 discloses a tablet containing a high content of magnesium oxide particles, which has a short disintegration time of 10 seconds or less and is therefore easy to swallow. The tablet described in Patent Document 1 has the advantage of being easy to tablet and easy to form into a tablet. [Prior art documents] [Patent documents]

[0003] [Patent Document 1] JP 2003-146889 A Summary of the Invention [Problem to be solved by the invention]

[0004] In general, there has been a demand for further improvements in tablets that can suppress cracking and chipping during the manufacturing process. Furthermore, tablets may have identification information applied to their surfaces by, for example, printing with ink, and there has been concern that, for example, tablets may come into contact with each other during the tablet manufacturing process, causing chipping of the identification information.

[0005] An object of the present invention is to provide a tablet which suppresses the occurrence of defective appearance. [Means for solving the problem]

[0006] The present disclosure provides, for example, the following aspects.

[0007] [Aspect 1] The tablet includes a columnar body, a cap, and a printed part. The cap has a shape that protrudes in the height direction of the body. Furthermore, the cap of the tablet has a printed part. The printed part is printed on the cap. The cap is circular when viewed from the height direction. The cap has a central part and a peripheral part. The central part spreads in a plane direction intersecting the height direction. The peripheral part is continuous with the outer edge of the central part. The surface of the central part has a non-printed area and a printed area. The non-printed area spreads in a circular shape from the center of the cap in the plane direction. The printed area is provided outside the non-printed area. When the diameter of the cap as viewed from the height direction is RC, the tablet has a radius of curvature R1 and a radius of curvature R2 within a range of ±10% of the value calculated by the following formula (1) and formula (2), respectively. The radius of curvature R1 indicates the radius of curvature on the surface of the central portion. The radius of curvature R2 indicates the radius of curvature on the surface of the peripheral portion. The non-printed area includes an area of ​​at least 2.6% of the surface area of ​​the cap portion. The non-printed area includes an area of ​​14.5% or less of the surface area of ​​the cap portion. The printed portion is provided in the printed area excluding the non-printed area. R1 = 3.226RC - 6.983 (1) R2 = 0.437RC - 0.231 (2)

[0008] [Aspect 2] In the tablet according to embodiment 1, the printed portion includes a plurality of characters arranged in a straight line.

[0009] [Aspect 3] In the tablet according to the first or second aspect, the cap portion is provided at least on one end of the body portion in the height direction.

[0010] [Aspect 4] The tablet according to any one of Aspects 1 to 3 is a tablet containing magnesium oxide as a main component.

[0011] [Aspect 5] The tablet is printed with ink containing a colorant, a resin, water, and ethanol in the tablet according to any one of Aspects 1 to 4. The content of the ethanol contained in the ink is 5 to 60% by weight based on the total weight of the ink composition. Effect of the Invention

[0012] The tablet according to the present invention can suppress the occurrence of defective appearance. [Brief description of the drawings]

[0013] [Figure 1] FIG. 2 is a plan view of the tablet according to the embodiment. [Diagram 2] 2 is a cross-sectional view taken along line II-II in FIG. [Diagram 3] 3A and 3B are diagrams for explaining an embodiment, in which FIG. 3A shows design 1 and FIG. 3B shows design 2. FIG. [Figure 4] FIG. 13 is a diagram for explaining an embodiment, used for classifying regions where character loss occurs. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0014] [tablet] Hereinafter, the shape of the tablet according to the embodiment of the present invention will be described with reference to the drawings. As shown in FIG. 1 and FIG. 2, the tablet 10 has a height direction H and a plane direction intersecting the height direction H, and includes a cylindrical body 12 having a predetermined length in the height direction H, cap parts 14 provided at both ends of the body 12 in the height direction H, and a printed part 16 provided on the cap part 14. The tablet 10 is not particularly limited in consideration of ease of taking as an oral agent, but for example, the upper limit of the diameter can be 14 mm or less or 10 mm or less, and the lower limit can be 5 mm or more or 6 mm or more. The upper limit of the length in the height direction H is also not particularly limited, but can be 8 mm or less or 7 mm or less, and the lower limit can be 3 mm or more or 4 mm or more.

[0015] The cap portion 14 of this embodiment has the same shape at both ends in the height direction H of the body portion 12. Of the cap portion 14 at both ends in the height direction H of the body portion 12, only the cap portion 14 provided on the upper side in the height direction H will be described as a representative. The cap portion 14 has a surface protruding in the height direction H. The height of the cap portion 14 indicates the apex 15 of the cap portion 14 from the upper end 13 as one end of the body portion 12. In the case of FIG. 2, the height of the cap portion 14 is the height to the center of the cap portion 14 (hereinafter referred to as the "cap depth") LH. The height of the cap portion 14 is not particularly limited, but is preferably 0.6 mm or more and 1.0 mm or less, and more preferably 0.7 mm or more and 0.9 mm or less. The cap portion 14 has a central portion 18 that spreads in the surface direction and a peripheral portion 20 that is continuous with the outer edge of the central portion 18. In FIG. 1, a dashed line 22 indicates the boundary between the central portion 18 and the peripheral portion 20. The central portion 18 is a disk-shaped portion that is radially inward of the cap portion 14 from the dashed line 22 .

[0016] The central portion 18 has a non-printed region 24 and a printed region 26 on the surface. The printed region 26 is an annular region that spreads outside the non-printed region 24. The non-printed region 24 is a region that spreads in a circular shape from the center of the cap portion 14 in the surface direction. The non-printed region 24 includes an area of ​​at least 2.6% of the surface area of ​​the cap portion 14. The non-printed region 24 is an area of ​​14.5% or less of the surface area of ​​the cap portion 14. The surface area of ​​the cap portion 14 is the area of ​​the cap portion 14 in a planar view. Specifically, the surface area of ​​the cap portion 14 is the area of ​​a shape formed by connecting the intersections of a straight line parallel to the height direction H that passes through the outer edge of the cap portion 14 when the tablet 10 is placed on a plane and the cap portion 14 is viewed from the height direction H with the plane. That is, since the cap portion 14 viewed from the height direction is a circle with a diameter RC, the surface area of ​​the cap portion 14 is the area of ​​a circle with a diameter RC. 1 and 2, the tablet 10 has a cylindrical body 12. The diameter of the body 12 and the diameter of the cap portion 14 are the same.

[0017] In FIG. 1, the two-dot chain line 28 indicates the boundary between the non-printed region 24 and the printed region 26. In other words, the two-dot chain line 28 indicates the outer edge of the region that spreads out in a circular shape from the center of the cap portion 14 in the planar direction. The non-printed region 24 is appropriately set within a region that occupies an area of ​​2.6% to 14.5% of the surface area of ​​the cap portion 14. The non-printed region 24 is a disk-shaped region radially inward of the two-dot chain line 28. The printed region 26 is an annular region that extends radially outward from the two-dot chain line 28 to the outer edge of the cap portion 14. The outer edge (not shown) of the printed region 26 is appropriately set within a region that occupies an area of ​​33% to 68% of the surface area of ​​the cap portion 14.

[0018] The peripheral portion 20 is an annular portion outside the dashed dotted line 22. The peripheral portion 20 includes the outer edge of the cap portion 14. At least a portion of the peripheral portion 20 is connected to the body portion 12. The inner edge of the peripheral portion 20 is connected to the central portion 18. The outer edge of the peripheral portion 20 is connected to the upper end 13 of the body portion 12. The outer edge of the printing area 26 may be inside the boundary (dashed dotted line 22) between the central portion 18 and the peripheral portion 20.

[0019] As shown in FIG. 2, which is a cross-sectional view including the central axis of the body 12, the radius of curvature R1 of the surface of the central portion 18 and the radius of curvature R2 of the surface of the peripheral portion 20 are each within a range of ±10% of the values ​​calculated by the following formulas (1) and (2), respectively. R1 = 3.226RC - 6.983 (1) R2 = 0.437RC - 0.231 (2)

[0020] Here, RC is the diameter of the cap portion 14 in a plan view. In the case of this embodiment, the diameter RC of the cap portion 14 is the same as the diameter of the body portion 12 of the tablet 10. A value within ±10% of the value calculated by the above formula (1) is hereinafter referred to as the value represented by the above formula (1). Similarly, a value within ±10% of the value calculated by the above formula (2) is hereinafter referred to as the value represented by the above formula (2).

[0021] The surface of the peripheral portion 20 preferably has an approach angle α with respect to the height direction H of 30 degrees or more and 35 degrees or less, more preferably 30 degrees or more and 34 degrees or less. In this specification, the approach angle α refers to the angle between the horizontal direction and the tangent TL of the surface of the peripheral portion 20. In the case of this embodiment, the horizontal direction is a direction parallel to the straight line connecting the upper ends 13 of the body portion 12 in the height direction H in the II-II line cross-sectional view. The position of the boundary (dotted line 22) between the central portion 18 and the peripheral portion 20 based on the center of the cap portion 14 is represented by the radial length LX and the height direction length LH, and the coordinates represented by LX and LH are called the intersection coordinates C. In addition to the portion having the radius of curvature R2, the peripheral portion 20 may have an outer end portion having a larger radius of curvature of the surface and a smaller surface area.

[0022] The printed part 16 is provided in the printed area 26 of the cap part 14 excluding the non-printed area 24. The printed part 16 is formed by printing, which applies ink to the surface of the cap part 14 in the printed area 26. For example, in the case of printing, the size, thickness, and font of the printed part 16 are not particularly limited as long as the printed part 16 can be visually recognized. For example, as shown in FIG. 1, the printed part 16 may include the mass of the active ingredient contained in the tablet 10 and the product name of the tablet 10. In addition, the printed part 16 may be colored in a different color for each type of tablet 10 depending on the mass of the active ingredient contained in the tablet 10.

[0023] The printed section 16 preferably includes a plurality of characters arranged, for example, in a line in the printing area 26. The printed section 16 has excellent visibility because the plurality of characters constituting the identification information are arranged in a line. The printed section 16 may include a plurality of characters arranged, for example, in a ring in the printing area 26. The printed section 16 can ensure a larger number of characters by arranging the plurality of characters constituting the identification information in a ring compared to when the characters are arranged in a line.

[0024] The tablet 10 has a radius of curvature R1 of the surface of the central portion 18 that is the value expressed by the above formula (1). The tablet 10 has a radius of curvature R2 of the surface of the peripheral portion 20 that is the value expressed by the above formula (2), so that the tablet 10 can be made stronger, and cracking and chipping of the tablet 10 can be suppressed.

[0025] The non-printed region 24 is an area that is likely to come into contact with a flat surface when the tablet 10 is placed on the flat surface. Therefore, the non-printed region 24 is likely to come into contact with, for example, a conveying surface along which the tablet 10 is conveyed and with other tablets during the manufacturing process. By providing the printed portion 16 in the printed region 26 excluding the non-printed region 24, the tablet 10 is prevented from missing characters, for example, when the tablets 10 come into contact with each other during the manufacturing process of the tablet 10.

[0026] Since the radius of curvature R1 of the surface of the central portion 18 of the tablet 10 is a value expressed by the above formula (1), cracking and chipping of the tablet 10 can be more reliably suppressed. Similarly, since the radius of curvature R2 of the surface of the peripheral portion 20 of the tablet 10 is a value expressed by the above formula (2), cracking and chipping of the tablet 10 can be more reliably suppressed. Therefore, the tablet 10 of this embodiment can suppress the occurrence of cracking and chipping of printed characters, thereby suppressing the occurrence of poor appearance.

[0027] The tablet 10 can have a desired size and mass by including the body portion 12. Although the tablet 10 of this embodiment has been described as including the body portion 12, the present invention is not limited thereto. The tablet 10 may be formed only with the cap portion 14 without including the body portion 12. Furthermore, although the tablet 10 has been described as including the cap portion 14 on both ends of the body portion 12 in the height direction H, the present invention is not limited thereto, and the body portion 12 may have the cap portion 14 on only one side in the height direction H.

[0028] In the present embodiment, the case where the body 12 is cylindrical has been described, but the present invention is not limited thereto. For example, the body 12 is preferably rounded at the corners, and may be a triangular prism, an elliptical prism, a rectangular prism, or a polygonal prism. In addition, the term "cylindrical" is not necessarily limited to an elongated shape, and includes a shape in which the length in the plane direction is greater than the length in the height direction. In the case where the body 12 and the cap portion 14 have different shapes, a part of the body 12 may protrude outward in the plane direction from the outer edge of the cap portion 14. In the case where the body 12 and the cap portion 14 have different shapes, a part of the cap portion 14 may protrude outward in the plane direction from the body 12.

[0029] Although the tablet 10 has been described as having a printed portion 16 on each of the cap portions 14 provided at both ends of the body portion 12 in the height direction H, the present invention is not limited to this, and the tablet 10 may have a printed portion 16 on only one of the cap portions 14.

[0030] The tablet 10 may contain magnesium oxide as a main component. This makes it possible to obtain a tablet containing magnesium oxide as a main component, which is suppressed from cracking and chipping of the tablet and from missing printed characters. Furthermore, the tablet 10 is provided with the characteristics described below, which suppresses the occurrence of cracking and chipping of the tablet. Below, a detailed description is given of the case where the tablet 10 contains magnesium oxide as a main component.

[0031] [Wearability] In this specification, "friability" refers to an index of the friability and brittleness of the tablet 10 against impact, and can be measured by the method described in "Japanese Pharmacopoeia, 17th Edition, Reference Information, Tablet Friability Test Method." Specifically, for a number of tablets close to 6.5 g, a tablet friability meter (Toyama Sangyo Co., Ltd., tablet friability tester TFT-1200) is used to subject test tablets to abrasion at 100 revolutions (24 to 26 revolutions / min), and the initial tablet mass before abrasion and the tablet mass after abrasion are measured, and the friability can be calculated according to the following formula 3.

[0032]

number

[0033] The range of the friability of the tablet 10 of this embodiment, when measured by the above-mentioned method, may be less than 0.40% as an upper limit, and is preferably less than 0.35%, and more preferably less than 0.30%. On the other hand, since the lower the friability, the more desirable it is, no lower limit is set.

[0034] [Capping] In this specification, "capping" refers to the peeling off of the upper or lower surface of the tablet 10 as a cross-sectional piece. Capping occurs, for example, due to impact during tableting, transportation, and packaging during the tablet manufacturing process. The rate of capping occurrence can be determined by a cassette rotor test. More specifically, the rate of capping occurrence is determined by discharging tablets from a cassette rotor set at a height of 2 m and counting the number of capped tablets from the tablets that have fallen. The rate of capping occurrence is determined by testing, for example, 100 test tablets as a sufficient number. The rate of capping occurrence is determined by counting the number of tablets that have capped among the 100 test tablets tested, and calculating the percentage. For example, a cassette rotor manufactured by TOSHO, for Magmit Tablets 500 mg, can be used. In addition, when calculating the rate of capping occurrence, the floor material specifications used can be concrete trowel + epoxy floor coating material + paste method (thickness 2 mm) (ABC Shokai) Chemicrete E or equivalent specifications.

[0035]

number

[0036] The range of the capping incidence rate of the tablet 10 of this embodiment, when the above-mentioned measurement method is used, is preferably less than 12%, more preferably less than 11%, and even more preferably less than 10%. On the other hand, since the lower the capping incidence rate, the more desirable it is, no lower limit is particularly set.

[0037] [hardness] In this specification, "hardness" is an index of tablet hardness, and can be measured by a tablet hardness tester. For example, DC-50 manufactured by Okada Seiko Co., Ltd. can be used as the tablet hardness tester. For example, the hardness can be determined by measuring the tablet hardness in the diameter direction using a tablet hardness tester. If the tablet hardness is too low, the friability increases, so the lower limit is preferably 30N or more, more preferably 40N or more, and even more preferably 50N or more. On the other hand, since a higher hardness is desirable for tablets, no upper limit is particularly set.

[0038] [Collapse time] In this specification, the term "disintegration time" refers to an index of the ease of disintegration of a tablet in a solution. The disintegration time can be measured according to the 17th revised Japanese Pharmacopoeia, General Test Methods, Disintegration Test Method. The disintegration time can be determined by measuring the disintegration time using a disintegration tester. More specifically, the "disintegration time" is determined by measuring the disintegration time in water using a disintegration tester, using a test solution containing an appropriate number of test tablets, for example, 6 tablets. The disintegration tester can be, for example, a disintegration tester NT-20HS manufactured by Toyama Sangyo Co., Ltd. Tablets having an appropriate disintegration time are preferable because tablets that disintegrate in the oral cavity in a short time when taken and are easy to swallow can be provided. The upper limit of the appropriate disintegration time is 20 seconds or less, preferably 15 seconds or less, and more preferably 11 seconds or less. The lower limit of the appropriate disintegration time is not particularly limited, but is preferably 0.5 seconds or more, or 1 second or more.

[0039] [Cellulose and / or cellulose derivatives] As used herein, "cellulose" refers to a polymer formed by polymerizing β-glucose molecules in a linear chain via glycosidic bonds (C 10 O5) nIt refers to a linear polymer represented by the formula: and examples thereof include crystalline cellulose, microcrystalline cellulose, and powdered cellulose. The term "cellulose derivative" refers to a cellulose molecule in which a different substituent has been introduced into a hydroxy group through an ether bond or an ester bond, and examples thereof include methyl cellulose, ethyl cellulose, carboxymethyl cellulose, calcium carboxymethyl cellulose, sodium carboxymethyl cellulose, hydroxyethyl cellulose, hydroxypropyl cellulose, hydroxypropyl methyl cellulose, and low-substituted hydroxypropyl cellulose. The term "cellulose and / or cellulose derivative" as defined in this specification refers to at least one selected from the above-mentioned "cellulose" and "cellulose derivative". The term "low-substituted hydroxypropyl cellulose" refers to cellulose in which an extremely small amount of hydroxypropoxy group has been introduced into the glucose ring, that is, cellulose with a molar substitution of 0.2 to 0.4 that has been O-(2-hydroxypropyl)ized at a low level. The shape of such a cellulose derivative may be, for example, powder, particulate, or fine particle.

[0040] The cellulose and / or cellulose derivative may be, for example, various grades of CEOLUS (registered trademark) manufactured by Asahi Kasei Corp. Specifically, the cellulose and / or cellulose derivative may be crystalline cellulose such as CEOLUS (registered trademark) PH-101, UF-711, PH-102, PH-200, PH-301, PH-302, PH-20JP, UF-702, KG-802, or KG-1000.

[0041] [Magnesium oxide particles]

[0042] The magnesium oxide particles used in this embodiment are particles of magnesium oxide (MgO). The magnesium oxide particles used in this embodiment can be obtained by calcining magnesium hydroxide particles. For example, magnesium hydroxide having an average particle size of 1 to 10 μm as measured by a laser diffraction scattering method can be obtained by calcining at 600 to 1000° C. As the magnesium oxide particles, for example, heavy grade magnesium oxide manufactured by Kyowa Chemical Industry Co., Ltd., powder grade magnesium oxide manufactured by Konoshima Chemical Co., Ltd., or light grade and heavy grade magnesium oxide manufactured by Tomita Pharmaceutical Co., Ltd. can be used.

[0043] The magnesium oxide particles used in this embodiment may be in either powder or granular form, but granular form is more effective in preventing wear on the tablet press and can also produce high-content tablets 10 with better shape retention stability.

[0044] The magnesium oxide particles used in this embodiment may preferably have a predetermined particle size, although it is not limited thereto. The upper limit of the average particle size of the magnesium oxide particles measured by the laser diffraction scattering method may be, for example, 40 μm or less, 20 μm or less, or 10 μm or less. By setting the average particle size of the magnesium oxide particles to the above-mentioned upper limit or less, the suspended particle size at the time of tablet disintegration may become small, and an effect of obtaining a tablet with less roughness in the oral cavity may be obtained. On the other hand, the lower limit of the average particle size is not limited, but may be, for example, 0.25 μm or more, 0.5 μm or more, or 1 μm or more, in view of the manufacturing limit and cost-effectiveness.

[0045] The average particle size and average particle size of the magnesium oxide particles of the present embodiment and the magnesium hydroxide particles, which are the raw material thereof, can be measured by a measuring device using a laser diffraction scattering method. Measurement by the laser diffraction scattering method can be achieved, for example, by using a particle size distribution measuring device MT3300EX2 manufactured by Microtrackbell Corporation.

[0046] The bulk density of the magnesium oxide particles used in this embodiment may cause a decrease in hardness if it is too high, so the upper limit may be 0.8 g / mL or less, or 0.7 g / mL or less. On the other hand, if the bulk density is too low, capping and lamination may occur, so the lower limit may be 0.1 g / mL or more, or 0.2 g / mL or more. The bulk density may be measured, for example, using a 100 mL stainless steel cup (actual measured mass value (g) / 100 (mL)).

[0047] If the angle of repose of the magnesium oxide particles used in this embodiment is too large, it may lead to a decrease in fluidity and a variation in tablet mass during tableting, so the upper limit can be set to 50° or less, or 48° or less. On the other hand, since the lower the angle of repose, the more desirable it is, no lower limit is set. The angle of repose can be measured, for example, using a multi-tester MT-1 manufactured by Seishin Enterprise Co., Ltd.

[0048] [Porosity] From the viewpoint of the light resistance of the ink, the magnesium oxide particles used in this embodiment are preferably adjusted to have a porosity within a predetermined range. The porosity of the magnesium oxide particles is, for example, preferably 30.0% or more and 55.0% or less, more preferably 40.0% or more and 50.0% or less. By setting the porosity within the above range, the ink penetrates into the voids, making it difficult for light to reach the ink that has penetrated, and there are cases in which an effect is obtained in which the stability, light resistance, and even fading resistance of the ink are improved. Furthermore, the magnesium oxide particles can be further easily suppressed from bleeding or fading by blending ethanol, resin, etc. contained in the ink.

[0049] [Tablet ingredients] The tablet 10 may contain magnesium oxide as an active ingredient. The tablet 10 preferably contains granules containing magnesium oxide particles and an internal additive, and an external additive. In this case, the tablet 10 preferably contains at least cellulose and / or a cellulose derivative as the internal additive and / or the external additive. When the tablet 10 contains cellulose and / or a cellulose derivative as the internal additive and the external additive, the mass ratio of [cellulose and / or cellulose derivative contained as an internal additive]:[cellulose and / or cellulose derivative contained as an external additive] may be within a certain range.

[0050] The magnesium oxide particles are preferably contained in the granules together with the internal additive. If the content of the magnesium oxide particles is too high, the moldability may be insufficient. Therefore, the content of the magnesium oxide particles can be, for example, 90% by mass or less, or 88% by mass or less, based on the entire tablet 10. If the content of the magnesium oxide particles is too low, an additive with high compressibility and high plastic deformability can be blended. If an additive with high compressibility and high plastic deformability can be blended, the tablet 10 can have high moldability, but the cost per tablet will be high. Therefore, the content of the magnesium oxide particles is preferably, for example, 80% by mass or more, or 85% by mass or more, based on the entire tablet 10.

[0051] In the tablet 10 of this embodiment, the mass ratio of [cellulose and / or cellulose derivatives contained as internal additives]: [cellulose and / or cellulose derivatives contained as external additives] is within a certain range. In the tablet 10, an increase in hardness and a decrease in friability can be expected by increasing the ratio of the external additives contained. If the ratio of the external additives contained in the tablet 10 is increased too much, for example, the capping incidence rate will increase and the tube passability will decrease. Therefore, the mass ratio contained as an external additive is preferably set to an upper limit of 90 or less, for example, 88 or less, 85 or less, 80 or less, or 75 or less, when the mass of the cellulose and / or cellulose derivatives contained in the entire tablet 10 is taken as 100. The mass ratio contained as an external additive is preferably set to a lower limit of more than 20, for example, 21 or more, 22 or more, 23 or more, 24 or more, or 25 or more, when the mass of the cellulose and / or cellulose derivatives contained in the entire tablet 10 is taken as 100. On the other hand, if the proportion of the internal additive contained in the tablet 10 is too small, the compaction will be insufficient, resulting in the generation of many fine particles, which will tend to hold air, and the air will not be completely removed during subsequent tableting, which may result in the generation of capped tablets. Therefore, the tablet 10 needs to be formulated with a certain amount of internal additives, but conversely, if the proportion of the internal additive contained is too high, granules will be obtained that are compacted by granulation, and the granules will be less likely to be destroyed by further compaction during tableting. If the granules of the tablet 10 are less likely to be destroyed by further compaction during tableting, the moldability will decrease, that is, the friability will increase. Therefore, the mass ratio contained as an internal additive is preferably set to an upper limit of less than 80, assuming that the mass of the cellulose and / or cellulose derivative contained in the entire tablet 10 is 100. The mass ratio contained as an internal additive, when the mass of the cellulose and / or cellulose derivative contained in the entire tablet 10 is taken as 100, is more preferably, for example, an upper limit of 79 or less, 78 or less, 77 or less, 76 or less, or 75 or less. The mass ratio contained as an internal additive, when the mass of the cellulose and / or cellulose derivative contained in the entire tablet 10 is taken as 100, is more preferably, a lower limit of 10 or more, for example, 12 or more, 15 or more, 20 or more, or 25 or more.

[0052] Furthermore, if the content of cellulose and / or cellulose derivatives in the entire tablet 10 is too high, the cost per tablet increases, so it can be 20% by mass or less, 15% by mass or less, or 12% by mass or less relative to the entire tablet 10. If the content of cellulose and / or cellulose derivatives in the entire tablet 10 is too low, the effects of this embodiment may not be achieved, so it can be 5% by mass or more, 7% by mass or more, or 9% by mass or more relative to the entire tablet 10.

[0053] In the tablet 10 of this embodiment, the cellulose and / or cellulose derivatives defined above are preferably used as excipients or binders in both the internal additive and the external additive. Moreover, the cellulose and / or cellulose derivatives contained in the internal additive and the external additive may be the same or different.

[0054] In this embodiment, the internal additive refers to an additive containing one or more substances that are added to and mixed with the active ingredient before the granulation step in the manufacture of the tablet 10. Other additives may be added as the internal additive in addition to the cellulose and / or cellulose derivatives defined above. In particular, in order to adjust the disintegration time to the preferred value as described above, it is preferable to add a disintegrant such as croscarmellose sodium, corn starch, carmellose calcium, crospovidone, and carboxystarch sodium as the internal additive in addition to the cellulose and / or cellulose derivatives contained in the internal additive and the external additive at the specific ratio defined above. For example, Kiccolate (registered trademark) ND-2HS manufactured by Nichirin Chemical Industry Co., Ltd. can be used as the disintegrant. If the amount of the disintegrant is too large relative to the entire tablet 10, it may be difficult to mold the tablet 10. The upper limit of the disintegrant may be, for example, 5% by mass or less, or 3.5% by mass or less relative to the entire tablet 10. If the amount of the disintegrant is too small relative to the entire tablet 10, it may be difficult to disintegrate the tablet 10. The lower limit of the disintegrant can be, for example, 1% by mass or more, or 2% by mass or more, based on the entire tablet 10.

[0055] In this embodiment, the external additive refers to an additive that is added to the granules produced after the granulation step in the production of the tablet 10 and is compressed together with the granules. The additive includes one or more substances. The external additive may include other additives in addition to the cellulose and / or cellulose derivatives contained in the internal additive and the external additive at the specific ratio defined above. The external additive is preferably, for example, a lubricant. The external additive may not include cellulose and / or cellulose derivatives and may include a lubricant. Examples of the lubricant include stearic acid and its salts (Mg, Ca salts), and preferably stearates, among which magnesium stearate and calcium stearate are preferred. Too much lubricant may lead to delayed disintegration. The upper limit of the lubricant may be, for example, 2% by mass or less, 1.5% by mass or less, or 1.0% by mass or less, based on the entire tablet 10. Too little lubricant may adhere to the punch and die. The lower limit of the amount of lubricant added to the entire tablet 10 can be 0.2% by mass or more, 0.5% by mass or more, or 0.9% by mass or more.

[0056] The mass of tablet 10 of this embodiment, as a tablet containing magnesium oxide as an active ingredient, can be, for example, an upper limit of 1000 mg or less, or 800 mg or less, or 600 mg or less per tablet, and a lower limit of 10 mg or more, or 50 mg or more, or 100 mg or more.

[0057] The tablet 10 of this embodiment is orally administered as a pharmaceutical for humans or animals, for example, for antacidity, laxatives, and prevention of calcium oxalate urinary calculi. The tablet 10 of this embodiment can also be used as a supplement for humans or animals for magnesium supplementation and antihypomagnesemia. The dosage depends on the application, purpose, or condition. For example, when used as an antacid, 0.5 to 1.0 g per adult per day is orally administered in several divided doses in terms of magnesium oxide. When used as a laxative, 2 g per adult per day is orally administered in three divided doses before or after meals, or once before bedtime. When used as a prevention of calcium oxalate urinary calculi, 0.2 to 0.6 g per adult per day is orally administered with a large amount of water in terms of magnesium oxide. For other applications, it is taken within the range of the tolerable upper limit of magnesium. For example, the U.S. Dietary Reference Intakes for sources other than food are set at 350 mg of magnesium per day for healthy adults and 5 mg per kg of body weight per day for healthy children (Institute of Medicine (IOM). Food and Nutrition Board. "Dietary Reference Intakes: Calcium, Phosphorus, Magnesium, Vitamin D and Fluoride". Washington, DC: National Academy Press, 1997).

[0058] The pharmaceutical of this embodiment has been approved in Japan for use as an antacid, laxative, or to prevent the occurrence of urinary calcium oxalate stones, using the active ingredient. The internal additive and / or external additive may further contain one or more other optional ingredients, so long as they do not substantially impede the effects expected in each application, as well as the reduction in friability and the reduction in the incidence of capping. Examples of such other ingredients include, but are not limited to, various pharmacologic additives that are pharmacologic acceptable, such as colorants and flavoring agents. Any one of these ingredients may be used alone, or any two or more of them may be used in any combination and ratio.

[0059] [Tablet manufacturing method] The tablet 10 according to the present embodiment can be manufactured, for example, by granulating powder to form granules. Granulation is preferably dry granulation. For example, granules can be manufactured by granulating using a dry granulator. For example, the dry granulator RC-156 manufactured by Freund Corporation can be used as the dry granulator.

[0060] The granules obtained are then compressed into tablets. The compression pressure, as the punch pressure per tablet, can be, for example, an upper limit of 20 kN or less, or 18 kN or less, or 16 kN or less. The compression pressure, as the punch pressure per tablet, can be, for example, a lower limit of 2 kN or more, or 3 kN or more, or 4 kN or more. The shape of the punch can be appropriately selected according to the shape of the tablet 10.

[0061] When the tablet 10 is a tablet containing magnesium oxide as an active ingredient, the above-mentioned manufacturing method may include a step of mixing magnesium oxide particles with an internal additive containing cellulose and / or a cellulose derivative, a step of granulating the mixture to form granules, and a step of compressing the granules. Furthermore, when the tablet 10 is provided with an external additive, the above-mentioned tableting step may include a step of adding an external additive containing cellulose and / or a cellulose derivative to the granules and compressing the granules. When an external additive containing cellulose and / or a cellulose derivative is added to the granules, the method may be such that the mass ratio of [cellulose and / or cellulose derivative contained as an internal additive]:[cellulose and / or cellulose derivative contained as an external additive] is within the range of 75:25 to 10:90.

[0062] A printed part is formed in the printing area of ​​the cap part 14 by printing on the tablet after tableting. The printing method is not particularly limited, but for example, a dye ink or a pigment ink may be used to form the printed part by an inkjet printer. The coloring material contained in the dye ink or pigment ink is one that is approved as a food additive or that complies with the Pharmaceutical Affairs Law. Examples of such coloring materials that can be used include safflower red pigment, gardenia blue pigment, chlorophyll pigment, turmeric pigment, cacao pigment, squid ink pigment, titanium oxide, carbon powder, ferric oxide, food red No. 2, food red No. 3, food red No. 40, food red No. 102, food red No. 104, food red No. 105, food red No. 106, food blue No. 1, food blue No. 2, food yellow No. 4, food yellow No. 5, and food green No. 3.

[0063] The following description will be given taking ink used in printing with an inkjet printer as an example. For example, ink for inkjet printers contains a dye, water, ethanol, and a resin. In addition, for example, a water-soluble high-boiling organic solvent, an emulsifier, a pH adjuster, a flavoring agent, and a preservative may be blended as necessary. All of these ink compositions are preferably edible.

[0064] (dye) The coloring matter can be one or more selected from synthetic food coloring matter and natural food coloring matter. Examples of synthetic food coloring matter include tar-based coloring matter, natural coloring derivatives, natural synthetic coloring matter, and titanium dioxide. Examples of tar-based coloring matter include Food Red No. 2, Food Red No. 3, Food Red No. 40, Food Red No. 102, Food Red No. 104, Food Red No. 105, Food Red No. 106, Food Yellow No. 4, Food Yellow No. 5, Food Green No. 3, Food Blue No. 1, Food Blue No. 2, Food Blue No. 1 Aluminum Lake, Food Red No. 2 Aluminum Lake, Food Red No. 3 Aluminum Lake, Food Red No. 40 Aluminum Lake, Food Yellow No. 4 Aluminum Lake, Food No. 5 Aluminum Lake, and Food Blue No. 2 Aluminum Lake. Examples of natural pigment derivatives include copper chlorophyll, sodium copper chlorophyllin, and potassium norbixin, and examples of natural synthetic pigments include β-carotene and riboflavin.

[0065] Examples of natural food dyes include plant charcoal pigments, anthocyanin pigments, carotenoid pigments, quinone pigments, flavonoid pigments, betaine pigments, monascus pigments, and other pigments derived from natural products. Examples of anthocyanin pigments include red radish pigments, red cabbage pigments, red rice pigments, elderberry pigments, cowberry pigments, gooseberry pigments, cranberry pigments, salmonberry pigments, perilla pigments, sweet blueberry pigments, strawberry pigments, dark sweet cherry pigments, cherry pigments, hibiscus pigments, huckleberry pigments, grape juice pigments, grape skin pigments, blackcurrant pigments, blackberry pigments, blueberry pigments, plum pigments, white wortberry pigments, boysenberry pigments, mulberry pigments, purple sweet potato pigments, purple corn pigments, purple yam pigments, raspberry pigments, redcurrant pigments, loganberry pigments, and other anthocyanin pigments. Carotenoid pigments include annatto pigment, gardenia yellow, and other carotenoid pigments. Quinone pigments include cochineal pigment, lithospermum pigment, lac pigment, and other quinone pigments. Flavonoid pigments include safflower yellow, sorghum pigment, onion pigment, and other flavonoid pigments. Betaine pigments include beet red pigment. Monascus pigments include Monascus pigment and Monascus yellow pigment. Other pigments derived from natural products include, for example, turmeric pigment, gardenia blue pigment, gardenia red pigment, and spirulina blue pigment.

[0066] The content of the dye is preferably 0.1 to 10% by weight, more preferably 0.5 to 8% by weight, based on the total weight of the ink composition. If the content of the dye is less than 0.1% by weight, the printed color tends to be light and the visibility tends to be poor. If the content of the dye is more than 10% by weight, the ink viscosity increases, making it difficult to eject the ink normally, and printing defects tend to occur.

[0067] (ethanol) Ethanol is preferably, for example, fermented ethyl alcohol and sugarcane alcohol from natural brewing. The content of ethanol is preferably 5 to 60% by weight, more preferably 10 to 40% by weight, based on the entire composition of the ink. If the content of ethanol is less than 5% by weight, the ink tends to dry poorly. For example, if the ink has poor drying properties, such as taking 3 seconds or more to dry after printing, the ink may peel off during transportation after printing or adhere to other tablets and transportation surfaces, causing stains. If the content of ethanol is less than 5% by weight, the surface tension of the ink increases, and the printed ink is easily repelled by the surface of the tablet. In other words, the ink does not wet and spread on the surface of the tablet, so it is difficult to dry. If the ink does not wet and spread on the surface of the tablet, the contact area with the tablet surface is small, so the adhesion force is small, and there is a risk that the ink may peel off when rubbed, for example, even after 24 hours. If the content of ethanol is more than 60% by weight, the ink tends to dry and adhere easily within or around the opening of the inkjet nozzle. If the ink dries and blocks the openings, this can result in, for example, ejection problems and deviations in the flying direction of ejected ink, resulting in printing defects.

[0068] (Water-soluble high boiling point organic solvent) The water-soluble high-boiling organic solvent can be used to prevent the nozzle of the inkjet head from drying. The water-soluble high-boiling organic solvent can be, for example, one or more selected from propylene glycol and glycerin. The content of the water-soluble high-boiling organic solvent is preferably 1 to 60% by weight, more preferably 2 to 55% by weight, based on the entire ink composition. If the content of the water-soluble high-boiling organic solvent in the ink is less than 1% by weight, the ink tends to dry out in the inkjet nozzle, resulting in poor printing. If the content of the water-soluble high-boiling organic solvent in the ink is more than 60% by weight, the ink viscosity increases, causing the ink to be ejected normally, resulting in poor printing.

[0069] (resin) The ink may also contain an edible resin if necessary. Examples of the edible resin include shellac, gum arabic, starches, cellulose resins, vinyl acetate resins, and polyvinylpyrrolidone. One or more types of edible resins may be selected.

[0070] (emulsifier) The emulsifier may be selected from one or more water-soluble emulsifiers selected from, for example, lecithin, glycerin fatty acid ester, sucrose fatty acid ester, sorbitan fatty acid ester, propylene glycol fatty acid ester, and polyoxyethylene sorbitan fatty acid ester. The ink does not necessarily need to contain an emulsifier. When the ink contains an emulsifier, the content of the emulsifier is preferably 0.01 to 5% by weight, more preferably 0.1 to 2% by weight, based on the entire composition of the ink. If the content of the emulsifier is less than 0.01% by weight, the surface tension of the ink may be increased, and the ink may not be in an appropriate meniscus state at the nozzle opening. If the ink does not become in an appropriate meniscus state at the nozzle opening, the ink may not be ejected from the nozzle, or may not land at a specified position even if ejected, which may result in poor printing. In addition, if the content of the emulsifier is more than 5% by weight, the ink may thicken and precipitate over time, which may result in clogging of the nozzle, which may also result in poor printing.

[0071] (pH adjuster) The pH adjuster can adjust the pH of the ink to within a predetermined range. From the viewpoint of water resistance, the pH adjuster is preferably a component that volatilizes after printing. Examples of pH adjusters include ammonium hydroxide, ammonium carbonate, and ammonium chloride. Among them, from the viewpoint of not causing a problem of residue, it is preferable that the pH adjuster uses ammonium hydroxide or ammonium carbonate to adjust the pH. The porosity of the tablet can be measured, for example, by mercury intrusion using a pore size distribution measuring device. For example, the pore size distribution measuring device can be an Auto pore V9620 model manufactured by Micrometrics.

[0072] For stirring in preparing the ink, for example, a magnetic stirrer, a propeller stirrer, or a commonly used stirrer can be used.

[0073] In addition, when the ink contains a pigment such as vegetable charcoal pigment, titanium dioxide, or aluminum lake, the pigment must be dispersed. A dispersing machine can be used for the dispersion. Examples of the dispersing machine include a ball mill, a roll mill, a sand mill, and a bead mill.

[0074] The ink can be filtered by, for example, centrifugal filtration or filter filtration. EXAMPLES

[0075] The present invention will be described in more detail below with reference to examples. However, these examples are merely illustrative and are not intended to limit the present invention in any way.

[0076] <First Example> Evaluation of wear and capping [Prescription] In producing the tablets of this example, the recipe shown in the table below was used.

[0077] [Table 1]

[0078] Details of the raw materials in Table 1 are as follows: Magnesium oxide: Japanese Pharmacopoeia magnesium oxide (heavy grade) manufactured by Kyowa Chemical Industry Co., Ltd., crystalline cellulose: CEOLUS KG-1000 manufactured by Asahi Kasei Corporation, croscarmellose sodium: Kiccolate ND-2HS manufactured by Nichirin Chemical Industry Co., Ltd., calcium stearate: vegetable calcium stearate manufactured by Taihei Chemical Industry Co., Ltd. The physical properties of the magnesium oxide used in this example were measured and were as follows: Average particle size: 7.691 μm (measured by laser diffraction scattering method using Microtrackbell Co., Ltd. MT3300 EX2) Bulk density: 0.249g / mL (measured using a 100mL stainless steel cup (actual mass (g) / 100 (mL))) Angle of repose: 41.7° (measured using a multi-tester MT-1 manufactured by Seishin Enterprise Co., Ltd.)

[0079] [Manufacturing method] According to the above recipe, each raw material was weighed out on a 15,000 tablet scale using an electronic balance (Mettler Toledo, 5 kg capacity PB5001-S / FACT). 1.Mixing The weighed magnesium oxide and other raw materials were placed in a polyethylene bag (1100 mm x 600 mm) and the bag was shaken left and right 30 times to mix. 2. Granulation The mixture obtained was granulated using a dry granulator (Dry granulator RC-156 manufactured by Freund Corporation) under the following granulation conditions to produce granules.

[0080] [Table 2]

[0081] After granulation, the bulk density and particle size were measured by the following methods. Bulk density: Measured using a 100mL stainless steel cup (actual mass (g) / 100 (mL)) Particle size distribution: Measured using a particle size distribution analyzer (Seishin Enterprise Co., Ltd. Laser diffraction scattering particle size distribution analyzer LMS-2000e) 3.Tablet compression The mixed granules and external additives were compressed into tablets using a tablet press (KIKUSUI MFG. CO., LTD., small high-speed rotary tablet press, VIRG) under the following conditions. Tableting conditions: φ10.5mm punch, single punch Rotating disk speed: 45 rpm, thickness: 5.1 mm (preload thickness: 6.0 mm) Tableting was carried out using multiple types of punches and formulations 1 and 2. After tableting, the following evaluations were carried out. Mass: (Number of tablets tested: 10 tablets) Thickness: (Number of tablets tested: 5 tablets) Using a thickness gauge manufactured by Ozaki Seisakusho Co., Ltd. Hardness: (Number of tablets tested: 10 tablets) Using a load cell type benchtop hardness tester DC-50 manufactured by Okada Seiko Co., Ltd. Friability test: Using a tablet friability tester TFT-1200 manufactured by Toyama Sangyo Co., Ltd., the test was performed for 100 rotations (number of test tablets: as close as possible to 6.5g). Tableting status: Visually check tableting pressure / tableting problems The punch configuration and the evaluation results of the tablets compressed using the above recipe are shown in Table 3, and the measurement results after compression are shown in Table 4.

[0082] [Table 3]

[0083] [Table 4]

[0084] In the above table, "R1-R2-Cup" indicates R1, R2, and cap depth, respectively. From the above, good results were obtained in both capping and friability for the tablets molded using punches No. 2 and No. 3. Furthermore, the results of No. 3 showed that better results in friability and capping could be obtained by setting the approach angle to 34°. Furthermore, the results of No. 5 and No. 6 confirmed that, like No. 3, excellent results in friability and capping could be obtained by molding tablets using punches similar to No. 3.

[0085] <Second Example> Printing Evaluation According to the above-mentioned "manufacturing method", using pestle No. 3 in the first example above, magnesium oxide tablets were manufactured which contained granules containing magnesium oxide particles and an internal additive, and an external additive, and also contained at least cellulose and / or a cellulose derivative as the internal additive and the external additive, with the mass ratio of [cellulose and / or cellulose derivative contained as an internal additive]:[cellulose and / or cellulose derivative contained as an external additive] being within the range of 75:25 to 10:90.

[0086] Furthermore, a printed portion was formed on the tablet using dye ink or pigment ink by an inkjet printer method using the following device. ·Printing device Tablet printing device: Ikegami Tsushinki Co., Ltd. (TIE-4500P) Tablet printing inspection: Daiichi Jitsugyo Viswill Co., Ltd. (System TIPS-EX4-CD) The designs of the printed portion were of two types: tablet 100 shown in Fig. 3(A) and tablet 110 shown in Fig. 3(B). Tablet 100 has design 1, in which a character portion is formed as identification information over the entire cap portion 14. Tablet 110 has design 2, in which a character portion is formed as identification information over the portion excluding the non-printed area of ​​cap portion 14. The dye ink used contained Food Blue No. 1, water, ethanol, propylene glycol, and shellac.

[0087] [Vibration test] The obtained tablets were evaluated by a vibration test according to the method described below. Vibration test equipment: manufactured by IMV Corporation Test method: After filling 1,000 printed tablets into bottles, they were used as the final package (20 bottles) and tested in accordance with JIS Z0200 General principles for performance test methods for packaged goods and JIS Z0232 Vibration test methods for packaged goods. Vibration test conditions: Vibration test level 2, which simulates long-distance domestic or international transportation in a temperate climate, was performed with random vibration on the z-axis for 90 minutes. Evaluation method: After the test, the tablets were removed from the bottle and visually inspected to count the number of tablets with missing transfer marks or characters, and the frequency of occurrence was confirmed.

[0088] [Packaging test] The obtained tablets were evaluated by a packaging test according to the method described below. Automatic tablet packaging machine: Tosho Co., Ltd. (Xana-120) Test method: 1,000 printed tablets were loaded into a cassette for the packaging machine, the cassette was placed on the upper level of the packaging machine, and 200 packets in total were packaged, with 5 tablets per package. Evaluation method: After packaging, the tablets were removed from the packaging paper and the number of tablets with missing letters or transfer marks was visually counted to confirm the frequency of occurrence.

[0089] [Evaluation Results] The combinations of print design and ink, as well as the results of the vibration test and packaging test, are shown in the table below.

[0090] [Table 5]

[0091] It was confirmed that design 2 reduced the occurrence of transfer and character chipping more than design 1 (compare Example 2-1 with Comparative Example 2-1, and Examples 2-2 and 2-3 with Comparative Examples 2-2 and 2-3, respectively).

[0092] The following table shows the results of classifying the locations where missing letters occurred in tablets with missing letters into the regions shown in Figure 4. In tablet 100 shown in Figure 4, the four circles represented by dashed lines are regions that extend circularly from the center of cap portion 14 in the planar direction, with circle A representing an area that is 2.6% of the surface area of ​​cap portion 14, circle B representing an area that is 14.5% of the surface area of ​​cap portion 14, circle C representing an area that is 33.3% of the surface area of ​​cap portion 14, and circle D representing an area that is 68.2% of the surface area of ​​cap portion 14.

[0093] [Table 6]

[0094] In Table 6, region A is a circular surface surrounded by circle A, region B is an annular surface obtained by subtracting the surface surrounded by circle A from the surface surrounded by circle B, region C is an annular surface obtained by subtracting the surface surrounded by circle B from the surface surrounded by circle C, and region D is an annular surface obtained by subtracting the surface surrounded by circle C from the surface surrounded by circle D. From the above results, it was found that the character drop occurrence rate in region A, which has an area ratio of 2.6% to the cap part 14, and region B, which has an area ratio of 14.5% or less, is higher than the character drop occurrence rate in regions C and D outside the range. Therefore, it was confirmed that the occurrence of character dropout can be suppressed by providing a printed portion in the printed region outside the non-printed region, except for the non-printed region that includes 2.6% of the surface area of ​​the cap part 14 and is in the range of 14.5% or less.

[0095] <Third Example> [Prescription] Tablets were manufactured according to the formulation shown in the table below.

[0096] [Table 7]

[0097] [Table 8]

[0098] Details of the raw materials used in the above examples and comparative examples are as follows. Magnesium oxide: Kyowa Chemical Industry Co., Ltd., Japanese Pharmacopoeia Magnesium Oxide (heavy grade) Crystalline cellulose: Ceolus PH-101 (Examples 3-1 to 3-3, Comparative Examples 3-1 to 3-3), Ceolus UF-711 (Examples 3-4 to 3-6, Comparative Examples 3-4 to 3-6) manufactured by Asahi Kasei Corporation Croscarmellose sodium: Kiccolate ND-2HS, manufactured by Nichirin Chemical Industry Co., Ltd. Calcium stearate: Taihei Chemical Industry Co., Ltd. Calcium stearate (vegetable) The physical properties of the magnesium oxide used in this example were measured and were as follows: Average particle size: 7.691 μm (measured by laser diffraction scattering method using Microtrackbell Co., Ltd. MT3300 EX2) Bulk density: 0.249g / mL (measured using a 100mL stainless steel cup (actual mass (g) / 100 (mL))) Angle of repose: 41.7° (measured using a multi-tester MT-1 manufactured by Seishin Enterprise Co., Ltd.)

[0099] [Manufacturing method] According to the above recipe, each raw material was weighed out on a 15,000 tablet scale using an electronic balance (Mettler Toledo, 5 kg capacity PB5001-S / FACT). 1.Mixing The weighed magnesium oxide and the raw materials of the internal additives were placed in a polyethylene bag (1100 mm x 600 mm) and mixed by shaking the bag left and right 30 times. After the mixing process, the bulk density was measured using a 100 mL stainless steel cup (actual measured mass (g) / 100 (mL)). 2. Granulation The mixture obtained was granulated using a dry granulator (Dry granulator RC-156 manufactured by Freund Corporation) under the following granulation conditions to produce granules.

[0100] [Table 9]

[0101] After granulation, the following evaluation items were evaluated. Flake rate: The masses of the product (A) that has been subjected to a granulation process for 1 minute and the product (B) that has been sieved through a 1000 μm sieve from the product (A) that has been processed for 1 minute are measured and calculated using the following formula 5.

[0102]

number

[0103] Bulk density: Measured using a 100mL stainless steel cup (actual mass (g) / 100 (mL)) Particle size distribution: Measured using a particle size distribution analyzer (Seishin Enterprise Co., Ltd. Laser diffraction scattering particle size distribution analyzer LMS-2000e)

[0104] 3.Addition of external additives The granules and the weighed raw materials of the external additives were placed in a polyethylene bag (1100 mm x 600 mm), and the bag was shaken left and right 30 times to mix. After mixing, the following evaluation items were evaluated. Bulk density: Measured using a 100mL stainless steel cup (actual mass (g) / 100 (mL)) Angle of repose: Measured using the Multi-Tester MT-1 manufactured by Seishin Enterprise Co., Ltd. 4.Tablet compression The mixed granules and external additives were compressed into tablets using a tablet press (KIKUSUI MFG. CO., LTD., small high-speed rotary tablet press, VIRG) under the following conditions.

[0105] [Table 10]

[0106] After tableting, the following evaluation items were evaluated. Mass: (Number of tablets tested: 10 tablets) Thickness: (Number of tablets tested: 5 tablets) Using Peacock thickness gauge Hardness: (Number of tablets tested: 10 tablets) Using a load cell type benchtop hardness tester DC-50 manufactured by Okada Seiko Co., Ltd. Friability test: Using a tablet friability tester TFT-1200 manufactured by Toyama Sangyo Co., Ltd., the test was performed at 100 revolutions (number of test tablets: number of tablets as close as possible to 6.5g). Disintegration time: (Number of test tablets: 6 tablets), based on the 17th revised Japanese Pharmacopoeia, General Test Method / Disintegration Test Method. The disintegration time of the test tablets in water was measured using a disintegration tester (Toyama Sangyo Co., Ltd., Disintegration Tester NT-20HS). Tableting status: Visually check tableting pressure / tableting problems Suspended particle diameter D50 (μm): (Number of test tablets: 1 tablet) The suspended particle diameter was measured when the test tablet was suspended in water using a laser diffraction scattering type particle size distribution analyzer LMS-2000e manufactured by Seishin Enterprise Co., Ltd. Tube passability 5Fr: Remove the plunger of a catheter syringe (Nipro Corporation, Enteral Nutrition Infusion Set Syringe DS 20mL Catheter Yellow), place one tablet into the outer cylinder, return the plunger, suck up 20mL of 55℃ hot water, cap the tip of the cylinder and leave it for 5 minutes. After 5 minutes, rotate the catheter syringe 90 degrees back and forth 15 times by hand, then connect an enteral nutrition tube (Atom Medical, Atom Nutrition Catheter T; diameter 5Fr, length 120cm) and inject an additional 20mL of the suspension inside and ion-exchanged water for washing to check for tube blockage. This test was performed 3 times, and if the tube was not blocked, it was evaluated as "successful", and if it was blocked, it was evaluated as "unsuccessful". Calculation of compression rate in tableting process: Filling depth (a) and main compression thickness (b) are calculated using the following formula 6

[0107]

number

[0108] [result] The results of measuring the bulk density of the resulting mixture (mixture) after mixing are shown in the table below.

[0109] [Table 11]

[0110] [Table 12]

[0111] The bulk density of the mixture was within the range of 0.20 to 0.25 (g / mL) in both the Examples and Comparative Examples, and no significant difference was observed. The measurement results of each item of the granules (granulated products) after granulation are shown in the table below.

[0112] [Table 13]

[0113] [Table 14]

[0114] Regarding granulation properties, the more crystalline cellulose contained as an internal additive, the better the processing ability and flake rate, and the higher the bulk density of the granulated product. This leads to the conclusion that it is preferable to include a certain amount of crystalline cellulose in the internal additive. The measurement results after adding the external additive are shown in the table below.

[0115] [Table 15]

[0116] [Table 16]

[0117] When comparing the particle size after addition of external additives between Comparative Examples 3-1 and 3-4, which do not contain crystalline cellulose as an external additive, and Comparative Examples 3-3 and 3-6, which contain 100% crystalline cellulose as an external additive, an increase of 150 μm Pass was observed in Comparative Examples 3-3 and 3-6, but the angle of repose was in the range of 40° to 44°, with little difference observed, so it is considered that there is no difference in fluidity.

[0118] The measurement results of each item after tableting are shown in the table below.

[0119] [Table 17]

[0120] [Table 18]

[0121] As the mass ratio of crystalline cellulose contained as an external additive to crystalline cellulose contained as an internal additive increases (Comparative Example 3-1 → Comparative Example 3-3, Comparative Example 3-4 → Comparative Example 3-6), the hardness increases and the friability decreases, but the capping incidence rate increases and the aggregation of suspended particles is observed. As the mass ratio of crystalline cellulose contained as an external additive to crystalline cellulose contained as an internal additive increases, the proportion of uncompressed crystalline cellulose that can contribute to tablet formation increases, and the compression rate during tableting increases, which is thought to have led to an increase in hardness and a decrease in friability. On the other hand, since the compaction during granulation is insufficient, the fine particles that could not be made into flakes tend to entrap air, and the bulk density of the entire granules to be tableted also decreases due to the influence of the uncompressed crystalline cellulose added later, which is thought to be the cause of the increase in the capping incidence rate. In addition, in Comparative Example 3-3, in which the entire amount of crystalline cellulose is contained as an external additive, clogging was also observed in the tube passability test. Therefore, the mass ratio of crystalline cellulose contained as an external additive to reduce friability is preferably approximately 25 or more, and appropriately approximately 90 or less, when the mass of cellulose and / or cellulose derivatives contained in the entire tablet is taken as 100.

[0122] The tablet thickness after compression was in the range of 5.3 to 5.5 mm, with no significant difference observed. The disintegration time was within an appropriate range in both the Examples and Comparative Examples.

[0123] From the above results, it was found that, in particular, by adjusting the mass ratio of [cellulose and / or cellulose derivatives contained as internal additives]:[cellulose and / or cellulose derivatives contained as external additives] within the range of 75:25 to 10:90, for example, within the range of 75:25 to 20:80, particularly within the range of 75:25 to 25:75, magnesium oxide tablets capable of achieving both reduced friability and reduced capping incidence can be efficiently produced. Furthermore, such a ratio makes it possible to achieve both reduced friability and reduced capping incidence while ensuring physical properties required for tablet production, such as moldability, granulation ability, tableting ability, flowability, and tube passability, as well as physical properties required for magnesium oxide tablets, such as disintegrability. [Industrial Applicability]

[0124] INDUSTRIAL APPLICABILITY The present invention has extremely high applicability in industrial fields where tablets with less occurrence of appearance defects are required, particularly in the fields of pharmaceutical production and distribution. [Explanation of symbols]

[0125] 10 tablets 12 Torso 13 Top of the body 14 Cap part 15 Cap top 16 Printing Department 18 Central part 20 Periphery 22 dash-dotted line 24 Non-print area 26 Print area 28 Dash line 100 tablets 110 tablets H Height direction

Claims

1. A columnar body and A cap portion protruding in a height direction of the body portion; A printed portion is printed on the cap portion, The cap portion is It is circular when viewed from the height direction, A central portion extending in a plane direction intersecting the height direction; a peripheral portion continuous with an outer edge of the central portion, The surface of the central portion is a non-printing area that extends in a circular shape from the center of the cap portion in the surface direction; a printing area outside the non-printing area, When a diameter of the cap portion as viewed from the height direction is RC, a radius of curvature R1 of the surface of the central portion and a radius of curvature R2 of the surface of the peripheral portion are within a range of ±10% of values ​​calculated by the following formulas (1) and (2), respectively, in a cross-sectional view including the central axis of the body portion, the non-printed area comprises at least 2.6% of the surface area of ​​the cap portion and is no greater than 14.5% of the surface area of ​​the cap portion; A tablet, wherein the printed portion is provided in the printed area excluding the non-printed area. R1=3.226RC-6.983...(1) R2=0.437RC-0.231...(2)

2. The tablet according to claim 1 , wherein the printed portion includes a plurality of characters arranged in a straight line.

3. The tablet according to claim 1 , wherein the cap portion is provided at least at one end of the body portion in the height direction.

4. The tablet according to claim 1, wherein the tablet is a tablet containing magnesium oxide as a main component.

5. The tablet is printed with an ink containing a pigment, a resin, water, and ethanol; The tablet according to claim 1, wherein the content of the ethanol contained in the ink is 5 to 60% by weight based on the total weight of the ink composition.

Citation Information

Patent Citations

  • tablet

    JP2013224325A

  • Antacid and laxative tablet

    JP2003146889A